OBJECTIVE 101
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors which includes abdominal 102 obesity, hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-c), and 103 elevated blood glucose levels [1] , affecting 20-30% of adults suffering from MetS worldwide [2] . MetS 104 and its components are associated with a range of negative cardiovascular health outcomes [3] . Emerging 105 evidence suggests that MetS may also present an increased risk of dementia[4-7] and accelerated decline 106 of cognitive abilities such as visual working memory [8] and executive functioning [9, 10] . However, 107
while some studies indicate that MetS affects cognition over and above the sum of its individual 108 components [11, 12] , not all research has confirmed a synergistic effect of MetS criteria on cognitive 109 decline. The longitudinal Atherosclerosis Risk in Communities Study found that hypertension and 110 diabetes mellitus were associated with greater declines in processing speed, verbal memory, and 111 executive functioning in middle-aged men, whereas MetS as a whole was not [13] . Similarly, prospective 112 data of 2,476 older adults indicated that risk factors such as hyperinsulinemia and diabetes but not MetS 113 were associated with an increased risk of developing dementia [14] . Moreover, a large multi-centre study 114 of 7,087 community-dwelling older adults suggested that MetS does not predict development of 115 dementia any better than its' separate components [15] . It is therefore not yet clear whether MetS is a 116 better predictor of cognitive ageing than its individual components. The relationship between MetS and 117 cognition may be further complicated by concurrent inflammatory processes, with the first increasing 118 the latter and vice versa [11] . In people with MetS, some cross-sectional and longitudinal studies have 119 primarily observed poor cognitive performance [16] [17] [18] and mild cognitive impairment [19] in 120 individuals who present with high serum markers of inflammation. The inflammatory response should 121 therefore be considered when examining the association between MetS and cognitive ageing. We 122 present longitudinal findings from the European Male Ageing Study (EMAS), a multi-centre cohort 123 study of middle-aged and older men [20] . The main objective was to investigate whether baseline MetS 124 was associated with cognitive decline over time in ageing men. Furthermore, we aimed to examine the 125 impact of individual MetS components on cognitive ageing. Lastly, we explored potential interaction 126 effects of MetS and hs-CRP levels, a biomarker of inflammation, on the rate of cognitive decline.
Men who agreed to partake were invited to attend for physical and cognitive performance measures, an 136 interviewer-assisted questionnaire, and a fasting blood test. Follow-up assessments took place at a mean 137 of 4.4 (SD ± 0.3) years after the baseline measurements. Ethical approval was obtained in accordance 138 with local practice and institutional requirements in each centre. All participants gave their written 139 informed consent. 140
Interviewer-assisted questionnaire and anthropometry 141
The interviewer-assisted questionnaire included the Beck Depression Inventory-II (BDI) for subjective 142 depressive symptoms[21], the Physical Activity Scale for the Elderly (PASE) [22] , and questions 143 regarding smoking habits, alcohol consumption, and health. Height and weight were measured using 144 standard, calibrated instruments [20] . Current prescription and non-prescription medication use was self-145 reported by the participants. 146
Cardiovascular risk factors 147
Seated pulse and blood pressure was recorded following a rest period of 5 minutes using an automated 148 sphygmomanometer (Omron 500I, Omron Healthcare (UK), Ltd Milton Keynes, UK). Waist 149 circumference was measured three times using anthropometric tape, with the median value being used 150 for analyses. Morning phlebotomy was performed before 10am to obtain a fasting blood sample. 151
Analyses of triglyceride and HDL-c levels were performed in local centres with commercially available 152 enzymatic assays. The presence of metabolic syndrome was determined according to the National 153
Cholesterol Education Program Adult Treatment Panel-III (ATP-III) definition [1] . Participants were 154 classified as having MetS if three or more of the following criteria were met: waist circumference >102 155 cm, fasting triglyceride >1.7 mmol/l, fasting HDL-c <1.03 mmol/l, blood pressure >130/85 mmHg or 156 current use of anti-hypertensive medication, and fasting glucose >5.6 mmol/l or current use of anti-157 diabetic medication. Levels of hs-CRP were measured using a solid-phase chemiluminescent 158 immunometric assay (Immulite 2000 hs-CRP assay; Diagnostics Products Corporation, Siemens, 159
Deerfield, IL, USA) with a sensitivity of 0.1 g/l. The intra-and inter-assay coefficients of variation were 160 2.8% and 3.1%, respectively. 161
Cognitive performance 162
The EMAS cognitive test battery consisted of four tasks: the Rey-Osterrieth Complex Figure accurately as possible within a 5-minute time limit. In the Recall task, participants were asked without 167 previous warning to draw the figure from memory thirty minutes after completing the copy. Scoring 168 criteria were based on the original procedure, with a maximum score of 36 points. The CTRM assesses 169 visual recognition memory[24] and involves the sequential presentation of photographs of urban scenes 170 followed by a forced-choice recognition component. One point was given for each correctly identified 171 image, with a maximum score of 30. Finally, the DSST is a paper-and-pencil subtest from the Wechsler 172
Adult Intelligence Scale used to measure psychomotor speed and visual scanning [25] . Participants had 173 to substitute as many symbols for digits as possible within 60 seconds using a coding table. 174
Statistical analysis 175
Participants with incomplete cognitive or MetS data at baseline or follow-up were excluded from the 176 analyses. Characteristics of the study sample at baseline were compared by MetS status using Mann-177
Whitney U tests for continuous variables and χ 2 tests for dichotomous variables. Continuous cognitive 178 change was calculated by subtracting the baseline score from the follow-up score. In order to specifically 179 compare participants with significant cognitive decline to those who did not demonstrate cognitive 180 decline, cognitive change was also investigated as a categorical variable. Participants were divided into 181 the categories "Decline" (>1 SD decrease from baseline), "No change" (<1 SD change from baseline), 182 and "Improvement" (>1 SD increase from baseline). Furthermore, we examined the effect of persistent 183 
RESULTS 201

Cohort characteristics 202
Of the men who participated in baseline assessments, 2,738 (86.1% of survivors) returned for follow-203 up measurements. A total of 698 participants was excluded from the analyses due to incomplete MetS 204 data, resulting in a final cohort of 1,913 participants for the ROCF tests and 1,965 participants for the 205 CTRM and DSST. Baseline characteristics of the sample by MetS status are shown in Table 1 . On 206 average, participants with MetS at baseline were older, showed more subjective depressive symptoms, 207
were less physically active, had higher levels of hs-CRP, consumed less alcohol, and were more likely 208
to have a history of heart disease or diabetes. The prevalence of MetS was 28.8% at baseline and 32.6% 209 at follow-up. A χ 2 test revealed that baseline MetS incidence differed significantly by centre (p <0.001), 210 ranging from 18.3% in Leuven to 44.2% in Szeged. The most common MetS criterion met was 211 hypertension (85%), followed by abdominal obesity (35%), hyperglycaemia (33%), 212 hypertriglyceridaemia (28%), and high HDL-c levels (13%). Mean cognitive scores on the ROCF Recall 213 and CTRM tasks improved slightly over time, while a decline was observed for the DSST (see Table 2 ). 214 A decline of 1SD or more from baseline occurred in 9.0% of participants on the ROCF Copy, 16.0% on 215 the ROCF Recall, 15.8% on the CTRM, and 20.8% on the DSST. Mann-Whitney tests showed that 216 participants who were lost to follow-up had lower baseline scores on the ROCF Copy (U = -9.01, p 217 <0.001), ROCF Recall (U = -8.87, p <0.001), CTRM (U = 6.85, p <0.001), and DSST (U = -11.21, p 218 <0.001) than those who returned for follow-up. Furthermore, a χ 2 test indicated that participants with 219
MetS at baseline were more likely to be lost to follow-up than those who did not have MetS (p < 0.001). 220
Metabolic syndrome and cognitive decline 221
Linear regression models of baseline MetS status, MetS components, and continuous cognitive decline 222 are summarised in Table 3 . In age-adjusted models, MetS, large waist circumference, and high blood 223
pressure were related to a better performance on the ROCF Recall. Furthermore, hypertriglyceridemia 224 was associated with a greater decline on the DSST. None of the associations were maintained after 225 adjusting for confounders such as education, physical activity, and centre. Furthermore, interaction 226 terms between age or BDI score and MetS or MetS components were not significant for any of the 227 cognitive tasks (all p >0.05). An increasing number of MetS components was related to better ROCF 228 and poorer DSST performance in age-adjusted but not fully-adjusted models (see Table 3 ). 229
When cognitive scores were investigated as categorical variables, there was a significant 230 negative association between baseline MetS and performance on the ROCF Copy and DSST in age-231 adjusted models (see Table 4 ). In addition, an increasing number of MetS components was related to a 232 worsening performance on the ROCF Copy, the CTRM, and the DSST. Of the individual components, 233 large waist circumference was related to poor performance on the DSST, high glucose levels correlated 234 with decline on the ROCF Copy, CTRM, and DSST, and high HDL-c was associated with decline on 235 the ROCF Recall. After adjusting for additional confounders, logistic regressions indicated that the 236 relationship between glucose levels and decline on the ROCF Copy and DSST remained significant. 237
When these associations were analysed separately for participants <65 years and participants ≥65 years 238 at baseline, only the correlation between ROCF Copy change remained significant for older (β = -0.74, 239 p <0.01) but not younger participants (β = -0.19, p = 0.541). Finally, persistent MetS was associated 240 with greater decline on the DSST in age-adjusted (β = -1.02, p <0.01) but not fully adjusted models (β 241 = -0.81, p = 0.225). There were no significant associations between persistent MetS and decline on the 242 ROCF or CTRM tasks (data not shown). 243
Cognitive decline and hs-CRP 244
Baseline hs-CRP levels were not independently associated with decline on any of the four tasks in either 245 age-or fully-adjusted linear regression models (all p >0.05). Furthermore, there were no significant 246 interaction effects of hs-CRP and MetS on cognitive performance on either the ROCF Copy (β = -0.37, 247 p = 0.220), the ROCF Recall (β = -0.32, p -0.501), the CTRM (β = -0.32, p = 0.317), or the DSST (β = 248 0.12, p = 0.750). 249
CONCLUSIONS 250
In this cohort of ageing European men, we found no evidence for a longitudinal association between 251 baseline MetS status or the cumulative effect of its components and cognitive decline over a mean period 252 it has been suggested that MetS affects cognition more strongly in women than in men[5,10,15,35,36], 266 although the reverse pattern has also been observed [18] . Genetic dissimilarities may make women more 267 vulnerable to the influence of vascular risk factor on the brain than men [15] , which could explain the 268 null findings in our all-male cohort. However, little is known about possible biomechanisms which could 269 account for a gender-dependent association between MetS and cognition and additional research is 270
needed. 271
While there is thus no conclusive evidence for a relationship between MetS and cognitive 272 ageing, prior research has frequently reported associations between the individual MetS components 273 and cognition. While the majority of studies indicates that hyperglycaemia or diabetes [18, 20, 33, 37] and 274 hypertension [13, 18, 33, 37] in particular are detrimental to cognitive functions, others suggest that HDL-275 c levels [38] or hypertriglyceridemia[9] are most strongly related to cognitive ageing. The present study 276 supports previous findings that hyperglycaemia presents a risk factor of cognitive decline, with raised 277 glucose levels correlating with declines in visuoconstructional abilities and processing speed. Therefore, 278
hyperglycaemia and/or diabetes may be driving associations between MetS and cognitive decline. 279
Possible mechanisms by which hyperglycaemia could affect cognitive functions include increases in 280
early pre-programmed cell death[37] and microvascular disease [38] . Although we found that waist 281 circumference, blood pressure, and hypertriglyceridemia were also related to ROCF Recall and DSST 282 performance, these associations were mainly explained by confounding factors. Previous studies which 283 did not correct for the influence of these confounders may have overestimated the effect of these risk 284 factors on cognition. Variance in age of the participants from different studies may also explain some 285 of the conflicting findings, as it has been proposed that the influence of MetS components changes with 286 age [39] . The present findings suggested that high glucose levels may be particularly detrimental to 287 cognitive functioning in individuals aged 65 and over. However, we found no other age-related effects 288 of MetS components on cognition in any of our regression models when including an interaction term 289 between age and the individual components. Nevertheless, as our sample was relatively young, our 290 findings may not be comparable to those studies investigating people aged 85 years and over. 291
Finally, some studies have indicated that the relationship between MetS and cognition is 292 modified by inflammation, with the combined presence of MetS and high hs-CRP levels being 293 associated with greater declines in global cognition [11, 18, 40] and non-amnestic mild cognitive 294 impairment [19] . However, we found no evidence of an association between hs-CRP levels, MetS, and 295 cognitive decline. Once again, this may be due to differences in population characteristics and cognitive 296 assessments. For example, the longitudinal Sacramento Area Latino Study of Aging (SALSA), which 297 found that high CRP levels were associated with greater cognitive decline in older adults with MetS 298 than low CRP levels, used measures of global cognition and verbal abilities to examine cognitive 299 decline [41] . It is possible that the cognitive tasks used in the present study, which focused on 300 visuospatial functioning and processing speed, were unable to capture potential interaction effects of 301
MetS and inflammation. In addition, studies investigating the relationship between CRP, the metabolic 302 syndrome, and cognition tend to define high and low inflammation based on distributions within the 303 participant sample [16, 42] rather than using a pre-specified value. A wide variety of values has therefore 304 been used to define 'high' inflammation, making it difficult to establish how CRP levels relate to MetS 305 and cognition. Other biomarkers such as interleukin-6 (IL-6), homocysteine, and α1-antichymotrypsin 306 may be more strongly correlated with cognitive decline [43] . Alternatively, some studies have used a 307 combination of inflammatory markers, such as CRP and IL-6 measures, to define high inflammation 308
rather than investigating the biomarkers in isolation [16] . Future research including or combining other 309 inflammation biomarkers may contribute to our understanding of the role of inflammation in the 310 relationship between MetS and cognition. 311
Major strengths of EMAS are its prospective and multi-centre design and the broad range of 312 physiological and performance measures collected. One limitation is that our assessment of cognitive 313 domains was constrained by the necessary use of culture-and language-fair instruments. We therefore 314 cannot draw conclusions about the effects of MetS on semantic abilities in men. In addition, performance 315 on the ROCF and CTRM tasks may be influenced by a practice effect, as underscored by an average 316 improvement in scores over time, resulting in an underestimation of cognitive decline in our cohort. 317
However, when we investigated the participants with the greatest cognitive decline in a sub-analysis, 318 we also did not find a significant association with MetS. As we did not have information about the 319 presence of MetS prior to our baseline measurements, we were not able to investigate the influence of 320 any long-term duration of MetS on cognition. However, we found no association between persistent 321
MetS over 4.4 years and cognitive function. We cannot exclude that a longer duration could be an 322 important factor in predicting cognitive decline, as a study of middle-aged adults indicated that MetS 323 was only related to decline in verbal abilities if the syndrome persisted over 10 years [44] . However, the 324 Caerphilly Prospective Study also found no association between length of MetS exposure and cognitive 325 performance in a group of middle-aged men over 14 years [35] . It is therefore not yet clear whether the 326 duration of MetS is related to cognitive decline. As we conducted multiple tests to investigate the 327 relationship between metabolic syndrome and cognitive decline, there was an increased risk of Type I 328 errors. Although the results therefore need to be interpreted with caution, the absence of an association 329 between MetS and cognition in any of our analyses reinforces our conclusion that the syndrome may be 330 unrelated to cognitive decline. Another limitation to our study is that participants lost to follow-up on 331 average had lower cognitive scores and were more likely to have MetS. It is therefore possible that 332 individuals with MetS showing the greatest cognitive impairments were not included in this study. 333
Moreover, we acknowledge that a relatively small number of participants showed significant cognitive 334 decline on several of the tasks used. Although we cannot exclude the possibility that the present study 335 lacked power to investigate associations with cognitive decline, the significant relationships between 336 cognition and hyperglycaemia suggest that this is not the case. 
